Stock Events

Stock Events

Enliven Therapeutics 

$42.36
971
-$3.77-8.17% Today

Statistics

Day High
47
Day Low
41.42
52W High
48.53
52W Low
14.79
Volume
2,608,354
Avg. Volume
1,276,971
Mkt Cap
2.51B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.57
-0.49
-0.4
-0.32
Expected EPS
-0.40145
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-178.05MNet Income

Analyst Ratings

59.25Average Price Target
The highest estimate is 62.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELVN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing directly with Enliven Therapeutics' cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, directly competing with Enliven Therapeutics.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. has a broad range of oncology products that compete in the same market as Enliven Therapeutics' cancer treatments.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC has a strong focus on oncology, with a portfolio that competes with Enliven Therapeutics in developing cancer therapies.
Novartis
NVS
Mkt Cap292.07B
Novartis AG focuses on innovative healthcare solutions, including oncology, where it competes with Enliven Therapeutics in the cancer treatment space.
Roche
RHHBY
Mkt Cap332.67B
Roche Holding AG, through its pharmaceuticals division, is a leader in oncology, directly competing with Enliven Therapeutics in cancer drug development.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. is known for its strong presence in the oncology market, offering competitive therapies to those developed by Enliven Therapeutics.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies including oncology, which puts it in direct competition with Enliven Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals, Inc. is involved in the discovery and development of pharmaceutical products for the treatment of cancer, among other diseases, competing with Enliven Therapeutics.

Regions

About

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Show more...
CEO
Mr. Samuel S. Kintz M.B.A.
Employees
62
Country
United States
ISIN
US29337E1029

Listings

XNAS
US
ELVN
ARCX
US
IMRA
BOATS
BOATS
ELVN.BOATS

0 Comments

Share your thoughts

FAQ

What is Enliven Therapeutics stock price today?▼
The current price of ELVN is $42.36 USD — it has decreased by -8.17% in the past 24 hours. Watch Enliven Therapeutics stock price performance more closely on the chart.
What is Enliven Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enliven Therapeutics stocks are traded under the ticker ELVN.
Is Enliven Therapeutics stock price growing?▼
ELVN stock has risen by +25.96% compared to the previous week, the month change is a +2.47% rise, over the last year Enliven Therapeutics has showed a +93.34% increase.
What is Enliven Therapeutics market cap?▼
Today Enliven Therapeutics has the market capitalization of 2.51B
When is the next Enliven Therapeutics earnings date?▼
Enliven Therapeutics is going to release the next earnings report on August 19, 2026.
What were Enliven Therapeutics earnings last quarter?▼
ELVN earnings for the last quarter are -0.38 USD per share, whereas the estimation was -0.44 USD resulting in a +14.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enliven Therapeutics revenue for the last year?▼
Enliven Therapeutics revenue for the last year amounts to 0 USD.
What is Enliven Therapeutics net income for the last year?▼
ELVN net income for the last year is -178.05M USD.
How many employees does Enliven Therapeutics have?▼
As of June 15, 2026, the company has 62 employees.
In which sector is Enliven Therapeutics located?▼
Enliven Therapeutics operates in the Health & Wellness sector.
When did Enliven Therapeutics complete a stock split?▼
The last stock split for Enliven Therapeutics was on February 24, 2023 with a ratio of 1:4.
Where is Enliven Therapeutics headquartered?▼
Enliven Therapeutics is headquartered in Boulder, United States.